Zacks: Analysts Anticipate Heron Therapeutics Inc (HRTX) to Announce -$0.46 Earnings Per Share
Equities research analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will report earnings of ($0.46) per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.34). Heron Therapeutics reported earnings of ($0.97) per share in the same quarter last year, which suggests a positive year over year growth rate of 52.6%. The business is scheduled to announce its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($2.26) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($1.98). For the next financial year, analysts forecast that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($1.44) to $0.45. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative net margin of 326.79% and a negative return on equity of 72.23%. The business had revenue of $19.79 million during the quarter, compared to analyst estimates of $19.84 million. During the same quarter in the prior year, the business earned ($0.77) earnings per share. The firm’s revenue was up 130.9% compared to the same quarter last year.
HRTX opened at $27.16 on Wednesday. Heron Therapeutics has a 12 month low of $14.95 and a 12 month high of $42.90. The company has a market capitalization of $2.21 billion, a P/E ratio of 7.44 and a beta of 1.45.
In other news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares of the company’s stock, valued at $192,420. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,701,494 shares of company stock valued at $96,553,796. 16.20% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the company. Allianz Asset Management GmbH boosted its position in Heron Therapeutics by 1,040.8% during the third quarter. Allianz Asset Management GmbH now owns 1,887,391 shares of the biotechnology company’s stock valued at $59,736,000 after purchasing an additional 1,721,947 shares during the last quarter. BlackRock Inc. boosted its position in Heron Therapeutics by 29.4% during the second quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock valued at $176,563,000 after purchasing an additional 1,032,010 shares during the last quarter. Rubric Capital Management LP boosted its position in Heron Therapeutics by 71.8% during the third quarter. Rubric Capital Management LP now owns 1,958,850 shares of the biotechnology company’s stock valued at $61,998,000 after purchasing an additional 818,603 shares during the last quarter. FMR LLC boosted its position in Heron Therapeutics by 6.5% during the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock valued at $438,654,000 after purchasing an additional 693,699 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Heron Therapeutics during the second quarter valued at $15,249,000.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.